317 related articles for article (PubMed ID: 31199879)
21. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
Barrientos JC; Ayed AO; Cha A; Du S; Fang B; Hall R; Marks SM; Peng E; Rhodes JM; Ryan K; Winters SB; Yeung PL; Hou JZ
Target Oncol; 2023 Sep; 18(5):727-734. PubMed ID: 37728835
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Kim ES; Dhillon S
Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
[TBL] [Abstract][Full Text] [Related]
24. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
25. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Brown JR; Eichhorst B; Hillmen P; Jurczak W; Kaźmierczak M; Lamanna N; O'Brien SM; Tam CS; Qiu L; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Wang MD; Fu L; Li J; Wu K; Cohen A; Shadman M
N Engl J Med; 2023 Jan; 388(4):319-332. PubMed ID: 36511784
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
Iskierka-Jażdżewska E; Hus M; Giannopoulos K; Mądro E; Hołojda J; Piotrowska M; Zaucha JM; Piszczek W; Szeremet A; Wojciechowska M; Steckiewicz P; Knopińska-Posłuszny W; Osowiecki M; Drozd-Sokołowska J; Kumiega B; Kyrcz-Krzemień S; Hałka J; Dudziński M; Wieszczy P; Robak T; Warzocha K; Jamroziak K
Leuk Lymphoma; 2017 Oct; 58(10):2485-2488. PubMed ID: 28278701
[No Abstract] [Full Text] [Related]
27. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
UK CLL Forum
Haematologica; 2016 Dec; 101(12):1563-1572. PubMed ID: 27756834
[TBL] [Abstract][Full Text] [Related]
28. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.
Hampel PJ; Ding W; Call TG; Rabe KG; Kenderian SS; Witzig TE; Muchtar E; Leis JF; Chanan-Khan AA; Koehler AB; Fonder AL; Schwager SM; Slager SL; Shanafelt TD; Kay NE; Parikh SA
Leuk Lymphoma; 2019 Nov; 60(11):2712-2719. PubMed ID: 31014142
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Mato AR; Nabhan C; Barr PM; Ujjani CS; Hill BT; Lamanna N; Skarbnik AP; Howlett C; Pu JJ; Sehgal AR; Strelec LE; Vandegrift A; Fitzpatrick DM; Zent CS; Feldman T; Goy A; Claxton DF; Bachow SH; Kaur G; Svoboda J; Nasta SD; Porter D; Landsburg DJ; Schuster SJ; Cheson BD; Kiselev P; Evens AM
Blood; 2016 Nov; 128(18):2199-2205. PubMed ID: 27601462
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib for treatment of chronic lymphocytic leukemia.
Vela CM; McBride A; Jaglowski SM; Andritsos LA
Am J Health Syst Pharm; 2016 Mar; 73(6):367-75. PubMed ID: 26953281
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
Br J Haematol; 2018 Aug; 182(4):504-512. PubMed ID: 29873072
[TBL] [Abstract][Full Text] [Related]
33. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
[TBL] [Abstract][Full Text] [Related]
34. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.
Jain P; Keating MJ; Wierda WG; Sivina M; Thompson PA; Ferrajoli A; Estrov Z; Kantarjian H; O'Brien S; Burger JA
Clin Cancer Res; 2017 May; 23(9):2154-2158. PubMed ID: 27797975
[No Abstract] [Full Text] [Related]
35. Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).
Jamroziak K; Szymczyk A; Hus M; Wojciechowska M; Knopinska-Posłuszny W; Hołojda J; Hałaburda K; Warzocha K; Iskierka-Jażdżewska E
Eur J Haematol; 2018 Apr; 100(4):389-391. PubMed ID: 29243346
[No Abstract] [Full Text] [Related]
36. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
37. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
38. The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
Akpinar S; Dogu MH; Celik S; Ekinci O; Hindilerden IY; Dal MS; Davulcu EA; Tekinalp A; Hindilerden F; Ozcan BG; Hacibekiroglu T; Erkurt MA; Bagci M; Namdaroglu S; Korkmaz G; Bilgir O; Cagliyan GA; Ozturk HBA; Serin I; Tiryaki TO; Ozatli D; Korkmaz S; Ulas T; Eser B; Turgut B; Altuntas F
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):169-173. PubMed ID: 34629286
[TBL] [Abstract][Full Text] [Related]
39. Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
Zhou Y; Lu H; Yang M; Xu C
Medicine (Baltimore); 2019 Aug; 98(33):e16915. PubMed ID: 31415440
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
Gordon MJ; Jones JE; George B; Peterson C; Burger JA; Jain N; Keating M; Wierda WG; Durand JB; Ferrajoli A
Cancer; 2023 Jul; 129(14):2192-2200. PubMed ID: 37016930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
